The JADA ® System for treatment of abnormal postpartum uterine bleeding, and the team behind the product, join Laborie, strengthening the company's commitment to improving maternal health. Joining an ...

Laborie Medical Technologies Corp. secured a new gem for its maternal health with the acquisition of the Jada system from Organon & Co. The terms of the deal, first announced in November, included ...

The JADA ® System is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. Avoid excessive force when inserting ...

Please provide your email address to receive an email when new articles are posted on . The JADA system decreased abnormal postpartum uterine bleeding in vaginal and cesarean birth, regardless of ...

Organon & Co. OGN announced the completion of the divestiture of its JADA System to Laborie Medical Technologies Corp. The deal is worth up to $465 million, including $440 million paid at closing and ...

Organon (OGN) shares added ~3% in the premarket on Monday, even as the women’s health company lowered its full-year outlook despite better-than-expected Q3 2025 financials amid its plans to divest the ...

The MarketWatch News Department was not involved in the creation of this content. The JADA(R) System for treatment of abnormal postpartum uterine bleeding, and the team behind the product, join ...

(MENAFN- AETOSWire) (BUSINESS WIRE )--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today the ...